SARS-CoV-2, the virus that causes COVID-19, is more infectious than severe acute respiratory syndrome (SARS) and Middle East ...

CoV-2 proteins in the blood of long COVID sufferers could be a key factor in their ongoing symptoms. This discovery offers new insights into the complex nature of long COVID and potentially points ...

Scientists at the Icahn School of Medicine at Mount Sinai, in collaboration with colleagues in the field, have developed an ...

The novel coronavirus SARS-CoV-2 has an enzyme that can counteract a cell's innate defense mechanism against viruses, ...

Researchers are preparing for additional preclinical and potential clinical trials to evaluate AMETA’s therapeutic potential across various diseases.

Researchers found that vaccination rates decreased as the social vulnerability index quartile increased, especially among ...

Scientists at the Icahn School of Medicine at Mount Sinai, in collaboration with colleagues in the field, have developed an ...

A virus reservoir in the body may explain why some people experience long COVID symptoms. A recent study indicates that long ...

SARS-CoV-2 has an enzyme that can counteract a cell's innate defense mechanism against viruses, explaining why it is more infectious than the previous SARS and MERS-causing viruses. The discovery may ...

XEC has become the second most prevalent strain in the country, according to data released by the U.S. Centers for Disease Control and Prevention ( CDC ), representing more than 1 in 10 cases. But ...

Researchers at the Icahn School of Medicine have unveiled the AMETA Nanobody Platform, which effectively combats SARS-CoV-2 ...

Researchers evaluated protection conferred by a single COVID-19 mRNA vaccine dose vs a 2-dose series in the setting of high preexisting SARS-CoV-2 immunity.